- Deeply responding to the United Nations Sustainable Development Goals, leveraging technology and innovation as engines to advance healthcare equity and accessibility
- Continuously enhancing governance transparency and effectiveness, creating long-term value for all stakeholders
- Ongoing investment in talent development, fostering shared value with communities
- Accelerating climate change response measures, deepening environmental governance responsibilities
- Leading green biopharmaceutical solutions, empowering global customers in sustainable development
Hong KongApril 29, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), officially released its 2025 Sustainability Report. The report underscores the company’s firm commitment to placing sustainability at its core, continuously empowering global customers, advancing innovative biologic therapies to benefit patients worldwide, and creating long-term value for all stakeholders.
Dr. Chris Chen, CEO of WuXi Biologics and Chair of the ESG Committee, stated: “At WuXi Biologics, we firmly believe that long-term corporate success is inseparable from a sustained commitment to employee well-being, social responsibility, and the global environment. As a leader in sustainable development, we collaborate with all stakeholders to actively create social and environmental value. We empower global customers through end-to-end green CRDMO solutions for biologics and drive responsible development across the entire value chain.”
Continuously Enhancing Governance Transparency and Effectiveness
Guided by a systematic sustainability strategy, the company has established a robust corporate governance framework and clear management processes. Aligned with the UN Sustainable Development Goals, the company has set a scientific, measurable ESG target matrix and developed a comprehensive implementation roadmap, driving continuous improvement through regular performance tracking.
WuXi Biologics is committed to open and transparent communication with all stakeholders, aiming to build long-term, trust-based partnerships. As an active participant in the Pharmaceutical Supply Chain Initiative (PSCI), the company fully adheres to PSCI principles and collaborates with global suppliers to promote responsible practices in key areas such as business ethics, human rights and labor, health and safety, environment, and management systems. In 2025, the company obtained ISO 20400 sustainable procurement system certification, further strengthening supply chain resilience. The company has also established a comprehensive system covering intellectual property, trade secrets, and data privacy protection across all processes, forming multiple lines of defense in systems, technology, and management to ensure the implementation of protective measures. Additionally, the company continues to enhance corporate resilience and risk management capabilities, successfully obtaining ISO 22301 business continuity management system certification, providing stable support for global operations and public health responses.
Empowering Talent Development and Shared Community Value
WuXi Biologics highly values the contributions of its global employees, who possess outstanding professional expertise and diverse backgrounds, representing 51 countries and regions. The company actively supports women’s career development in Science, Technology, Engineering, and Mathematics (STEM) fields, with women currently accounting for 54% of STEM positions, significantly higher than the industry average.
At the same time, community engagement is a vital part of the company’s positive social impact. In 2025, company employees contributed over 12,000 hours of volunteer service in local communities, continuously contributing to community development.
Furthermore, WuXi Biologics actively promotes the deep integration of employee value and community value: fostering a spirit of volunteerism, organizing employees to participate in public welfare initiatives, effectively fulfilling corporate responsibility, and promoting social resilience building.
Leveraging Technology and Innovation as Engines to Drive Global Healthcare Equity and Accessibility
WuXi Biologics is always committed to shortening the time “from molecule to patient.” By building a global, large-scale, end-to-end integrated CRDMO platform, the company enhances the accessibility and affordability of innovative biologics, contributing long-term value to advancing global healthcare equity and improving public health.
Leveraging its core technological capabilities, WuXi Biologics actively responds to global public health events, empowering partners to advance the development of innovative therapies for patients worldwide. In 2025, WuXi Biologics partnered with the Butantan Institute and the Butantan Foundation in Brazil to help scale up the commercial production of the dengue vaccine (Butantan-DV), continuously enhancing local public health protection capabilities. The company’s relevant facility has received GMP certification from the Brazilian Health Regulatory Agency (ANVISA).
In the rare disease field, as of the end of 2025, the company’s platform hosted 23 rare disease projects and has enabled the launch of three rare disease drugs. In May 2025, partner CANbridge Pharmaceuticals announced that its innovative rare disease treatment product, velaglucerase beta for injection (brand name: Gerunin®), received marketing approval from China’s National Medical Products Administration (NMPA), marking a significant breakthrough in advancing innovative therapies for rare diseases.
Additionally, the company focuses on community health support through various projects, including emergency response, primary healthcare reconstruction, disease relief, and community health assistance, continuously supporting local health system development and extending healthcare accessibility to the “last mile.”
From global public health responses to individual patient care, WuXi Biologics leverages its platform technological capabilities, global resilient network, and world-class quality system to accelerate global healthcare accessibility and safeguard global health.
Accelerating Climate Change Response, Deepening Environmental Governance Responsibilities
WuXi Biologics continuously strengthens its environmental governance and leadership in areas such as climate change response, efficient resource utilization, circular economy practices, ecosystem protection, and green innovation.
In 2025, WuXi Biologics’ new greenhouse gas emission reduction target matrix received validation from the Science Based Targets initiative (SBTi). At the same time, the company achieved its target of reducing water use intensity by 30% compared to the 2019 baseline and implemented excellent water management programs at 10 sites. To promote industry sustainability, the company released the “WuXi Biologics Green CRDMO White Paper,” systematically showcasing green R&D and production practices for biologics, as well as the significant energy-saving and emission-reduction results achieved through green operations.
To continuously enhance operational excellence, WuXi Biologics deeply integrates its WBS lean management system with its sustainability strategy. In 2025, over 95% of WBS improvement projects achieved ESG results, playing a positive role in reducing carbon emissions, decreasing water consumption, and minimizing waste.
Global Recognition, Co-creating the Future
WuXi Biologics’ sustained investment in sustainable development has been recognized by several internationally authoritative ESG rating agencies, including the highest MSCI ESG AAA rating, EcoVadis Platinum Medal, inclusion in the Dow Jones Best Index (formerly Dow Jones Sustainability Index), CDP “A List” for climate change, water security, and supplier engagement, Sustainalytics’ highest “Negligible Risk” rating, inclusion in the FTSE4Good Index Series, ISS ESG “Prime” rating, and inclusion in the Hang Seng Corporate Sustainability Benchmark Index. These accolades fully demonstrate the company’s outstanding performance in the field of sustainable development.
Dr. Chris Chen stated: “Looking ahead, WuXi Biologics will continue its strong growth momentum, leveraging its leading capabilities in biologics research, development, and manufacturing to drive accelerated business growth. With sustainability at the core of our innovation, operations, and growth, we will continue to empower global customers, advance innovative biologic therapies to benefit patients worldwide, create long-term value for all stakeholders, and collectively move towards a healthy future.”
To view the full WuXi Biologics 2025 Sustainability Report, please visit:
https://www.wuxibiologics.com.cn/wp-content/uploads/C_898490_WUXI-BIO_ESG2025_0429_1652_ESS.pdf
About WuXi Biologics
WuXi Biologics (Stock Code: 2269.HK) is a global leading Contract Research, Development, and Manufacturing Organization (CRDMO). Through its open-access, integrated biologics capabilities and technology platform, the company provides comprehensive end-to-end services to help partners discover, develop, and manufacture biologics, enabling the entire process from concept to commercial production, accelerating global biologics R&D, reducing R&D costs, and benefiting patients worldwide.
Leveraging a global network connecting China, the United States, Ireland, Germany, and Singapore, WuXi Biologics brings together over 13,000 employees, including industry experts and scientists in biologics R&D and manufacturing, technological innovation, and operational excellence. With its leading technology platforms and deep expertise, the company provides efficient, cost-effective, and scalable biologics solutions tailored to meet customer needs at different stages. Furthermore, the company systematically integrates digital capabilities and infrastructure into the full value chain of biologics R&D, laboratory operations, and manufacturing, transforming data, computing, and predictive capabilities into a more transparent customer collaboration experience, faster R&D processes, smarter operational management, and more efficient production delivery. As of the end of December 2025, WuXi Biologics was supporting a total of 945 integrated projects for customers, including 74 Phase III clinical projects and 25 commercial manufacturing projects, with complex molecule projects accounting for over 50% of the company’s total project portfolio.
WuXi Biologics regards sustainable development as the cornerstone of long-term business growth. The company continuously promotes green innovative technologies, providing global partners with advanced end-to-end green CRDMO solutions, while consistently achieving excellence in ESG. Upholding the concept of creating shared value, the company collaborates with stakeholders to build a sustainable development ecosystem, promoting both social value and ecological benefits through responsible operational models, achieving synergistic empowerment across the entire value chain.
For more information, please visit: www.wuxibiologics.com.
For more information, please contact
ESG
Media Relations